← Leaderboards
Carlos L Arteaga
Vanderbilt University
$27,881,034
Attributed
$28,698,348
Total exposure
41
Grants
40
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$94,504,195 · 43
By mechanism
P50$42,096,409 · 22
P30$39,586,523 · 15
R01$10,294,773 · 4
T32$2,526,490 · 2
Top collaborators
- Laura Carpin Kennedy3 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Brent N Rexer$1,140,154
- Benjamin Christian Hacker$78,323
- Ingrid M Meszoely$205,573
- Michael Ian Miga$9,976,365
- Yuankai Kenny Tao$4,151,264
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsResearch PersonnelMalignant Breast NeoplasmFundingClinical TrialsResourcesTranslational ResearchBaseMalignant NeoplasmsGrantBreastPilot ProjectsCancer CenterResistanceCollaborationsCancer Center Support GrantClinical ResearchDrug ResistanceMolecularMemberBasic ScienceAnticancer ResearchEstrogen AntagonistsLeadership
Grant awards (156)
UT Southwestern Medical Center Simmons Comprehensive Cancer Center$4,376,925
P30 · FY2025 · CA · contact PI
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer$578,023
R01 · FY2025 · CA
Leadership, Planning, and Evaluation$243,163
P30 · FY2025 · CA · contact PI
Cancer Center Administration Core$243,163
P30 · FY2025 · CA · contact PI
UT Southwestern Medical Center Simmons Comprehensive Cancer Center$4,306,073
P30 · FY2024 · CA · contact PI
Leadership, Planning, and Evaluation$562,614
P30 · FY2024 · CA · contact PI
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer$546,296
R01 · FY2024 · CA
Cancer Center Administration Core$437,014
P30 · FY2024 · CA · contact PI
UT Southwestern Medical Center Simmons Comprehensive Cancer Center$4,306,073
P30 · FY2023 · CA · contact PI
Leadership, Planning, and Evaluation$562,614
P30 · FY2023 · CA · contact PI
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer$510,310
R01 · FY2023 · CA
Developmental Funds$470,665
P30 · FY2023 · CA · contact PI
Cancer Center Administration Core$437,014
P30 · FY2023 · CA · contact PI
Addressing Colonoscopy Quality to Increase Capacity for Colorectal Cancer Screening (CCSG YR13)$49,331
P30 · FY2023 · CA · contact PI
UT Southwestern Medical Center Simmons Comprehensive Cancer Center$4,306,073
P30 · FY2022 · CA · contact PI
Leadership, Planning, and Evaluation$562,614
P30 · FY2022 · CA · contact PI
Developmental Funds$470,665
P30 · FY2022 · CA · contact PI
Cancer Center Administration Core$437,014
P30 · FY2022 · CA · contact PI
Role of HER2 mutations in breast cancer progression and response to targeted therapies$360,914
R01 · FY2022 · CA · contact PI
Mechanisms of resistance to endocrine therapy in ER positive breast cancer$324,752
P50 · FY2022 · CA · contact PI
Multidimensional single-cell approach probing HIV-1 integration association with non-AIDS defining cancers (Biospecimens/Biocohort)$250,000
P30 · FY2022 · CA · contact PI
Cancer Center Administration Core$250,000
P30 · FY2022 · CA · contact PI
UT Southwestern Medical Center Simmons Comprehensive Cancer Center$4,306,073
P30 · FY2021 · CA · contact PI
Leadership, Planning, and Evaluation$562,614
P30 · FY2021 · CA · contact PI
Developmental Funds$470,665
P30 · FY2021 · CA · contact PI
Cancer Center Administration Core$437,014
P30 · FY2021 · CA · contact PI
Role of HER2 mutations in breast cancer progression and response to targeted therapies$368,327
R01 · FY2021 · CA · contact PI
Mechanisms of resistance to endocrine therapy in ER positive breast cancer$332,774
P50 · FY2021 · CA · contact PI
Cancer Center Support Grant - UT Southwestern Medical Center$2,451,875
P30 · FY2020 · CA · contact PI
Role of HER2 mutations in breast cancer progression and response to targeted therapies$368,372
R01 · FY2020 · CA · contact PI
Mechanisms of resistance to endocrine therapy in ER positive breast cancer$337,466
P50 · FY2020 · CA · contact PI
Administrative Core and Senior Leadership$236,061
P30 · FY2020 · CA · contact PI
DEVELOPMENTAL FUNDS (Core-002)$163,458
P30 · FY2020 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM (Core-010)$80,143
P30 · FY2020 · CA · contact PI
Experimental Therapeutics of Cancer Scientific Program$45,512
P30 · FY2020 · CA · contact PI
PLANNING AND EVALUATION (Core-001)$40,902
P30 · FY2020 · CA · contact PI
Population Science and Cancer Control Scientific Program$28,221
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant - UT Southwestern Medical Center$2,430,000
P30 · FY2019 · CA · contact PI
Role of HER2 mutations in breast cancer progression and response to targeted therapies$357,364
R01 · FY2019 · CA · contact PI
Mechanisms of resistance to endocrine therapy in ER positive breast cancer$342,254
P50 · FY2019 · CA · contact PI
Cancer Center Support Grant - UT Southwestern Medical Center$201,060
P30 · FY2019 · CA · contact PI
Cancer Center Support Grant - UT Southwestern Medical Center$50,000
P30 · FY2019 · CA · contact PI
Cancer Center Support Grant - UT Southwestern Medical Center$2,480,000
P30 · FY2018 · CA · contact PI
Role of HER2 mutations in breast cancer progression and response to targeted therapies$382,641
R01 · FY2018 · CA · contact PI
Cancer Center Support Grant - UT Southwestern Medical Center$249,371
P30 · FY2018 · CA · contact PI
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br$207,475
P50 · FY2018 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$87,030
P30 · FY2018 · CA · contact PI
Admin/Outreach Core$72,598
P50 · FY2018 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$10,000
P30 · FY2018 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$7,998
P30 · FY2018 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$7,968
P30 · FY2018 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$4,817
P30 · FY2018 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$4,735
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant - UT Southwestern Medical Center$2,480,000
P30 · FY2017 · CA · contact PI
Admin/Outreach Core$372,490
P50 · FY2017 · CA · contact PI
Career Development Program$192,755
P50 · FY2017 · CA · contact PI
Developmental Research Program$192,754
P50 · FY2017 · CA · contact PI
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br$192,748
P50 · FY2017 · CA · contact PI
Cancer Center Support Grant - UT Southwestern Medical Center$175,000
P30 · FY2017 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$87,030
P30 · FY2017 · CA · contact PI
SPORE in Breast Cancer$2,162,000
P50 · FY2016 · CA · contact PI
SPORE in Breast Cancer$750,000
P50 · FY2016 · CA · contact PI
Admin/Outreach Core$372,009
P50 · FY2016 · CA · contact PI
Career Development Program$192,274
P50 · FY2016 · CA · contact PI
Developmental Research Program$192,273
P50 · FY2016 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$84,561
P30 · FY2016 · CA · contact PI
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br$59,554
P50 · FY2016 · CA · contact PI
SPORE in Breast Cancer$1,115,022
P50 · FY2015 · CA · contact PI
SPORE in Breast Cancer$1,069,978
P50 · FY2015 · CA · contact PI
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br$209,905
P50 · FY2015 · CA · contact PI
Developmental Research Program$209,900
P50 · FY2015 · CA · contact PI
Career Development Program$209,900
P50 · FY2015 · CA · contact PI
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br$101,899
P50 · FY2015 · CA · contact PI
Developmental Research Program$101,897
P50 · FY2015 · CA · contact PI
Career Development Program$101,896
P50 · FY2015 · CA · contact PI
Admin/Outreach Core$85,975
P50 · FY2015 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$84,561
P30 · FY2015 · CA · contact PI
Admin/Outreach Core$51,001
P50 · FY2015 · CA · contact PI
Breast Cancer Research Program (BC) (Project-004)$48,839
P30 · FY2015 · CA · contact PI
SPORE in Breast Cancer$2,161,998
P50 · FY2014 · CA · contact PI
Erbb2 targeted antitumor strategies in breast cancer$303,185
R01 · FY2014 · CA · contact PI
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br$277,546
P50 · FY2014 · CA · contact PI
Admin/Outreach Core$77,712
P50 · FY2014 · CA · contact PI
Career Development Program$65,806
P50 · FY2014 · CA · contact PI
Developmental Research Program$65,806
P50 · FY2014 · CA · contact PI
SPORE in Breast Cancer$2,150,500
P50 · FY2013 · CA · contact PI
Erbb2 targeted antitumor strategies in breast cancer$293,808
R01 · FY2013 · CA · contact PI
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br$153,608
P50 · FY2013 · CA · contact PI
Overall Critique$153,607
P50 · FY2013 · CA · contact PI
Program Organization and Capabilities$153,607
P50 · FY2013 · CA · contact PI
Scientific Collaborations$153,607
P50 · FY2013 · CA · contact PI
Patient Advocate Comments$153,607
P50 · FY2013 · CA · contact PI
Career Development Program$153,607
P50 · FY2013 · CA · contact PI
Developmental Research Program$153,607
P50 · FY2013 · CA · contact PI
SPORE in Breast Cancer$2,300,000
P50 · FY2012 · CA · contact PI
Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer$317,085
P50 · FY2012 · CA · contact PI
Erbb2 targeted antitumor strategies in breast cancer$312,562
R01 · FY2012 · CA · contact PI
Administrative and Outreach Core$128,050
P50 · FY2012 · CA · contact PI
Developmental Research Program$72,225
P50 · FY2012 · CA · contact PI
Career Development Program$72,224
P50 · FY2012 · CA · contact PI
SPORE in Breast Cancer$2,185,000
P50 · FY2011 · CA · contact PI
Erbb2 targeted antitumor strategies in breast cancer$312,060
R01 · FY2011 · CA · contact PI
Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer$302,518
P50 · FY2011 · CA · contact PI
Administrative and Outreach Core$121,969
P50 · FY2011 · CA · contact PI
Vanderbilt Training Program in Academic Cancer Research$109,327
T32 · FY2011 · CA · contact PI
Career Development Program$68,312
P50 · FY2011 · CA · contact PI
Developmental Research Program$68,311
P50 · FY2011 · CA · contact PI
SPORE in Breast Cancer$2,190,230
P50 · FY2010 · CA · contact PI
Erbb2 targeted antitumor strategies in breast cancer$320,163
R01 · FY2010 · CA · contact PI
Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer$304,568
P50 · FY2010 · CA · contact PI
Vanderbilt Training Program in Academic Cancer Research$223,678
T32 · FY2010 · CA · contact PI
Administrative and Outreach Core$122,589
P50 · FY2010 · CA · contact PI
Career Development Program$68,166
P50 · FY2010 · CA · contact PI
Developmental Research Program$68,166
P50 · FY2010 · CA · contact PI
SPORE in Breast Cancer$2,300,000
P50 · FY2009 · CA · contact PI
TGF-betas and Receptors and Human Breast Cells$327,478
R01 · FY2009 · CA · contact PI
Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer$320,837
P50 · FY2009 · CA · contact PI
Administrative and Outreach Core$129,109
P50 · FY2009 · CA · contact PI
Career Development Program$71,266
P50 · FY2009 · CA · contact PI
Developmental Research Program$71,266
P50 · FY2009 · CA · contact PI
SPORE in Breast Cancer$2,300,000
P50 · FY2008 · CA · contact PI
TGF-betas and Receptors and Human Breast Cells$327,478
R01 · FY2008 · CA · contact PI
Resistance to Antiestrogen Therapy in Hormone Receptor-Positive Breast Cancer$207,653
P50 · FY2008 · CA · contact PI
Administrative and Outreach Core$83,433
P50 · FY2008 · CA · contact PI
Career Development Program$46,000
P50 · FY2008 · CA · contact PI
Developmental Research Program$46,000
P50 · FY2008 · CA · contact PI
SPORE in Breast Cancer$2,360,642
P50 · FY2007 · CA · contact PI
Training Program in Breast Cancer Research$370,351
T32 · FY2007 · CA · contact PI
TGF-betas and Receptors and Human Breast Cells$327,034
R01 · FY2007 · CA · contact PI
Erbb2 targeted antitumor strategies in breast cancer$302,816
R01 · FY2007 · CA · contact PI
SPORE in Breast Cancer$2,431,145
P50 · FY2006 · CA · contact PI
TGF-betas and Receptors and Human Breast Cells$335,245
R01 · FY2006 · CA · contact PI
Training Program in Breast Cancer Research$323,852
T32 · FY2006 · CA · contact PI
Erbb2 targeted antitumor strategies in breast cancer$311,860
R01 · FY2006 · CA · contact PI
Training Program in Breast Cancer Research$52,919
T32 · FY2006 · CA · contact PI
SPORE in Breast Cancer$2,489,652
P50 · FY2005 · CA
TGF-betas and Receptors and Human Breast Cells$341,063
R01 · FY2005 · CA
Erbb2 targeted antitumor strategies in breast cancer$319,365
R01 · FY2005 · CA
Training Program in Breast Cancer Research$293,689
T32 · FY2005 · CA
SPORE in Breast Cancer$218,655
P50 · FY2005 · CA
SPORE in Breast Cancer$2,489,652
P50 · FY2004 · CA
Training Program in Breast Cancer Research$343,728
T32 · FY2004 · CA
Erbb2 targeted antitumor strategies in breast cancer$319,365
R01 · FY2004 · CA
HER(erbB) Inhibitors in Untreated Operable Breast Cancer$213,519
P50 · FY2004 · CA
SPORE in Breast Cancer$2,500,000
P50 · FY2003 · CA
Training Program in Breast Cancer Research$384,495
T32 · FY2003 · CA
TGF-BETAS AND RECEPTORS AND HUMAN BREAST CELLS$327,511
R01 · FY2003 · CA
Erbb2 targeted antitumor strategies in breast cancer$319,365
R01 · FY2003 · CA
TGF-BETAS AND RECEPTORS AND HUMAN BREAST CELLS$320,226
R01 · FY2002 · CA
ERBB2 TARGETED ANTITUMOR STRATEGIES IN BREAST CANCER$298,286
R01 · FY2002 · CA
TRAINING PROGRAM IN BREAST CANCER RESEARCH$216,964
T32 · FY2002 · CA
TGF-BETAS AND RECEPTORS AND HUMAN BREAST CELLS$312,702
R01 · FY2001 · CA
ERBB2 TARGETED ANTITUMOR STRATEGIES IN BREAST CANCER$291,687
R01 · FY2001 · CA
TRAINING PROGRAM IN BREAST CANCER RESEARCH$207,487
T32 · FY2001 · CA
TGF-BETAS AND RECEPTORS AND HUMAN BREAST CELLS$264,176
R01 · FY2000 · CA
ERBB2 TARGETED ANTITUMOR STRATEGIES IN BREAST CANCER$235,091
R01 · FY2000 · CA